Curriculum Vitae - European Leukemia Net

Curriculum Vitae
Rüdiger HEHLMANN, o. Prof. Dr. med. Dr. h. c.
Personal Data Business address: III. Medizinische Universitätsklinik,
Medizinische Fakultät Mannheim, Universität Heidelberg,
Pettenkoferstraße 22, 68169 Mannheim, Germany,
Tel.: +49-(0)-621-383-6931, Fax: +49-(0)-621-383-6932,
E-Mail: R.Hehlmann@urz.uni-heidelberg.de
Married to: Dr. Annemarie Hehlmann,
four children: Johannes, Karoline, Rüdiger, Corinna
Date and place of birth: May 10, 1941, Halle/Saale, Germany
Education
1961 - 1966 Study of Medicine at Marburg, Freiburg, Edinburgh, Munich
Graduation: December 1966
Stevenson Exchange Scholar, (Edinburgh) 1964-1965
Scholar Studienstiftung des Deutschen Volkes 1963-1969
1967 - 1969 Internship in Gynecology, Surgery and Medicine, Munich; MD-PhD Scholar,
Max Planck Institute for Biochemistry, Munich (P.H. Hofschneider)
Approval as Physician 30.6.1969, Dr. med.: 22.7.1969
Academic Career
1969 - 1970 Assistant, Max Planck Institute for Biochemistry, Munich
1970 Research Fellow, University of Rochester, New York (Stan Hattman)
1970 - 1972 Research Associate, Columbia University, New York (Sol Spiegelman)
1972 - 1973 Lecturer in Human Genetics and Development at Columbia University
1973 - 1974 Intern/Resident, Columbia-Presbyterian Medical Center
Licence to practice Medicine and Surgery in the State of New York, 16.09.1974
1974 DFG (German Research Council)-stipend, Memorial Sloan Kettering Cancer
Center
1974 - 1981 Assistant, Medizinische Poliklinik, Munich University (Nepomuk Zöllner)
1975 - 1988 Research at the Research Center GSF, Neuherberg (Volker Erfle)
1977 Approval as Internist
1979 Habilitation (Dr. med. habil)
1981 - 1988 Professor of Medicine, Munich University
1984 Approval as Hematologist and Oncologist
1988 – present Professor of Medicine, University of Heidelberg
1988 – 2007 Director of the III. Medizinische Universitätsklinik in Mannheim
1999 – 2001 Dean of the Mannheim Medical Faculty
1995 - 2009 President and Secretary General of the International Association for
Comparative Research and Leukemia and Related Diseases (IACRLRD)
2000 - 2001 President of the German Society for Hematology and Oncology
2009 Congress president, 14. Congress of the European Hematology Association,
Berlin

Research
Since 1970 search for a human leukemia virus which resulted in the detection of retrovirus-related
RNA and reverse transcriptase and in the isolation, in 1983, of a complete human
endogenous retrovirus related to a primate leukemia virus. In 1984, first HIVseroepidemiology
in Germany
Since 1982, shift of the research focus towards clinical trials on leukemias and start of the chronic
myeloid leukemia (CML) study group which resulted in major randomized studies
and, in line with the international development, a profound improvement of prognosis
and survival in CML.
Since 1992 European cooperation on clinical CML-research (European Investigators on CML).
Since 1997, in the search for new approaches to the understanding of carcinogenesis,
demonstration of the role of chromosomal aberrations (aneuploidy) for genetic
instability and the initial stages of cancer development in a hamster model (in
cooperation with Peter Duesberg) which resulted in the chromosomal theory of
carcinogenesis.
Since 1997, creation of the German competence network on acute and chronic leukemias in
cooperation with all major leukemia trial groups which improved and accelerated
leukemia research in Germany.
Since 2002 creation of the European LeukemiaNet (ELN) on the basis of the European
cooperation on CML and the German cooperation on leukemia. The ELN has
established common standards and guidelines for research and leukemia management
across Europe. From the very beginning the ELN was recognized by the Eastern
European countries as an ideal platform to join cooperation with their colleagues from
the west. ELN guidelines are internationally accepted as standards for diagnosis and
therapy.
Since 2007 Public private partnership of ELN with Novartis through the European Treatment and
Outcome Study (EUTOS) for CML to determine the epidemiology of CML in Europe,
to define standards for molecular monitoring and to spread excellence on CML
throughout Europe.
At present, consolidation of European cooperation and outreach to a global partnership including
other continents. First institutions in North America have become ELN members
(Cornell University) or are in the process to ELN membership.
Research support:
Two thirds public and foundations (EU, BMBF, Krebshilfe, Carreras etc.), one third industry.
Science Awards and Honours
1984 Curt Bohnewand-Prize for scientific cooperation in cancer research
1990 GSF-Prize for interdisciplinary cooperation
1999 Paul Martini-Prize for improvement of prognosis in CML
2000 Ehrenschild, Kulturverein Waldhof
2009 Johann Georg Zimmermann Medal for the treatment of leukemia
2012 Wilhelm Warner-Preis for the fight against cancer
2

2004 R.T. Silver-Lecture , Cornell University, New York
2006 Wiedermann-Lecture, Olmütz, Czechia
2007 Hofschneider Memorial Lecture, XXIII. IACRLRD-Symposium, Freiburg
2011 Jubilee lecture 50 years IACRLRD, Tokyo, Japan
2005 Honorary Member of the Polish Society for Hematology and Transfusion
Medicine
2008 Honorary Member of the German Society for Hematology and Oncology
2011 Honorary doctor of the University Uppsala, Sweden
Organization of Scientific Meetings
Organization of 48 international meetings and congresses
1992 - 2012 21 Annual International Workshops on CML in Weinheim, Mannheim and
Heidelberg
1997, 2005 XIX. and XXII. Symposium of the IACRLRD in Mannheim and Heidelberg
2001 Annual Congress of the German and Austrian Societies of Hematology and
Oncology in Mannheim
2003 11 th Annual Meeting of the European Investigators on CML in Berlin
1999 - 2003 4 Annual Symposia of the Competence Network “Akute und chronische
Leukämien” in Heidelberg
2004 - 2012 9 Annual Symposia of the German and European Leukemia Networks in
Heidelberg and Mannheim
2002 - 2012 10 Annual Meetings of the European LeukemiaNet at ASH conferences in
Philadelphia, Atlanta (2x), San Diego (3x), Orlando (2x), San Francisco and
New Orleans
Career-related Activities
1981 - 1988 Vice chairman of the Society for Morphology and Physiology, Munich
1986 - 1990 Vice chairman of the South-German Hemoblastosis Group (SHG)
1986 - 1996 Editor of the scientific journal “AIDS-Forschung”
1987 Advisor, AIDS-Hearing at the Bavarian Parliament (Bayerischer Landtag)
1987 - 1988 Advisor to the Enquete Commission on AIDS of the German Parliament
(Bundestag)
1989 - 1991 Delegate (Fachvertreter) of the German Ministry for Research and Technology
at the European Commission in Brussels concerning AIDS
1989 - 2009 Member (M.) of the World Committee of the International Association for
Comparative Research on Leukemia and Related Diseases (IACRLRD)
1996 M. of the Advisory Committee to the German Government on cost evaluation of
clinical university medicine
1993 - 1998 M. of the Review Committee of the German Ministry for Research and
Technology for Infectious Diseases
1995 - 1999 M. of the Review Committee of the German Ministry for Research and
3

Technology for Public Health
1995 - present M. of the Scientific Advisory Board of the German José Carreras Leukemia
Foundation
1996 - 2000 M. of the CML-Guidelines Committee of the American Society of Hematology
1996 - 2004 M. of the Advisory Board of the German Society for Hematology and Oncology
1997 - 2000 Delegate of the German Society for Hematology and Oncology to the Working
Party of Scientific Medical Societies (AWMF)
1996 - 2007 Section Editor for CML of the journal “Leukemia”
1996 - present M. of the Editorial Boards of the journals: Annals of Hematology, European
Journal of Medical Research and others
2001 - present M. of the Steering Committee of the German AML Intergroup
2002 - present Cofounder and Chairman of the Leukemia Foundation (in support of the
German Leukemia Net)
2009 - present Cofounder and Chairman of the ELN-Foundation (in support of the European
LeukemiaNet)
1990 - 2008 M. of the Steering Committee of the Cancer Center Heidelberg/Mannheim
2005 - 2007 M. of the Steering Committee of the Interdisciplinary Tumor Center Mannheim
(ITM)
Publications: 387 Medline, 125 non-medline (chapters, reviews etc.)
Selected Publications (2003- 2012)
Hehlmann R. How I treat CML blast crisis. Blood. 2012 Jul 26;120(4):737-47
Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti
G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Definitions,
methodological and statistical issues for phase III clinical trials in chronic myeloid leukemia: a proposal by the
European LeukemiaNet. Blood. 2012, 119(25):5963-71
Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for longterm
progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012
Sep;26(9):2096-102.
Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B,
Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD,
Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K,
Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R, SAKK and the German CML
Study Group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term
observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760-8
Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet
statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid
leukemia. Leukemia. 2011;25(9):1433-1438.
Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G,
Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. Predicting complete cytogenetic response and
subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood
2011 Jul 21;118(3):686-92
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et.al.. Tolerability-adapted
imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid
leukemia. J Clin Oncol. 2011;29(12):1634-42
Hehlmann R, Jung-Munkwitz S, Saussele S. Treatment of chronic myeloid leukemia when imatinib fails.
Expert Opin Pharmacother. 2011; 12(2):269-83.
4

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC,
Hehlmann R, et.al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and
Management Recommendations From European LeukemiaNet. J Clin Oncol. 2011, 29(6):761-70
Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui et.al.; European LeukemiaNet. The
European LeukemiaNet: achievements and perspectives. Haematologica. 2011; 96(1):156-62
Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A.
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus
Interferon Alfa in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2010, 28(8):1429-35.
Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C,
Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M,
Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R: Allogeneic
hematopoietic stem cell transplantation (alloSCT) for chronic myeloid leukemia in the imatinib era; evaluation
of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010, 115(10):1880-5
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A,
Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT,
Goldman J, Hehlmann R: Chronic myeloid leukemia: an update of concepts and management recommendations
of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51.
Hehlmann R, Hochhaus A, Baccarani M: Chronic Myeloid Leukemia. Lancet 2007, 370:342-50
Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O,
Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler
ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K,
Wassmann B, Falge C, Kirchner HH, Gratwohl A, the SAKK and the German CML-Study Group: Drug
Treatment is Superior to Allografting as First Line Therapy in Chronic Myeloid Leukemia. Blood 2007,
109:4686-4692
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes
J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver
R, Hehlmann R: Evolving concepts in the management of chronic myeloid leukemia. Recommendations from
an expert panel on behalf of the European Leukemianet. Blood 2006; 108:1809-20
Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC,
Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G,
Soverini S, Stock W, Goldman JM: Monitoring CML patients responding to treatment with tyrosine kinase
inhibitors - Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL
transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37
Maywald O, Pfirrmann M, Berger U, Breitscheidel L, Gratwohl A, Kolb HJ, Beelen DW, Metzgeroth G, Gnad
SU, Hochhaus A, Hasford J, Hehlmann R, Reiter A for the German CML Study Group and the SAKK:
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic
hematopoietic stem cell transplantation in chronic myeloid leukemia. Leukemia 2006; 20:477-84
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA,
Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann
R, Chase A, Cross NC: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses
PCM1 to JAK2. Cancer Res 2005; 65:2662-2667
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi
C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R,
Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC: Widespread occurrence of the JAK2 V617F mutation in
chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168
Hehlmann R, Berger U, Aul C, Büchner T, Döhner H, Ehninger G, Ganser A, Gökbuget N, Hoelzer D, Überla
K, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann W, Ottmann OG,
Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Böhme A, Harrison-Neu E, Griesshammer M,
Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B, Niederwieser D, Heil G, Müller T,
Hasford J: The German competence network 'Acute and chronic leukemias'. Leukemia 2004; 18:665-669
Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld
DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H,
Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S,
Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H. Randomized comparison of interferon alpha and
hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of
survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003; 17:1529-1537
5